Current Oncology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
Inflammatory markers as prognostic factors of recurrence in advanced stage squamous cell carcinoma of the head and neck.
27:135-141.
2020
-
A catalyst for transforming health systems and person-centred care: Canadian national position statement on patient-reported outcomes.
27:90-99.
2020
-
Canadian consensus: A new systemic treatment algorithm for advanced EGFR-mutated NSCLC.
27:e146-e155.
2020
-
Immuno-oncology—the new paradigm of lung cancer treatment.
27:S78-S86.
2020
-
Organizational guidance for the care of patients with head-and-neck cancer in Ontario.
27:e115-e122.
2020
-
Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum.
27:e34-e42.
2020
-
Systemic adjuvant therapy for adult patients at high risk for recurrent cutaneous or mucosal melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline.
27:e43-e52.
2020
-
The evolving field of bone imaging in multiple myeloma: is it time to abandon skeletal surveys?.
27:10-11.
2020
-
Trends in survival based on treatment modality in patients with pancreatic cancer: a population-based study.
27:e1-e8.
2020
-
OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing.
26:e618-e623.
2019
-
An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.
26:240-246.
2019
-
Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.
26:e551-e557.
2019
-
Lessons learned from a cancer knowledge translation grants program: results of an evaluation.
26:272-284.
2019
-
Psychedelics for psychological and existential distress in palliative and cancer care.
26:225-226.
2019
-
Resource use in the last three months of life by lung cancer patients in southern Ontario.
26:247-252.
2019
-
Incidence of radionecrosis in single-fraction radiosurgery compared with fractionated radiotherapy in the treatment of brain metastasis.
26:e328-e333.
2019
-
Initial management of small-cell lung cancer (limited- and extensive-stage) and the role of thoracic radiotherapy and first-line chemotherapy: a systematic review.
26:e372-e384.
2019
-
Renal cell carcinoma in the Canadian Indigenous population.
26:e367-e371.
2019
-
Surgery after chemoradiotherapy in patients with stage III (N2 or N3, excluding T4) non-small cell lung cancer: a systematic review.
26:e398-e404.
2019
-
Establishing funding rates for colonoscopy and gastroscopy procedures in Ontario.
26:98-101.
2019
-
Surgical attitudes toward preoperative breast magnetic resonance imaging in women with early-stage breast cancer.
26:e194-e201.
2019
-
Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.
26:e81-e93.
2019
-
Integrating primary care providers through the seasons of survivorship.
26:48-54.
2019
-
A Little Help from My Friends: Social Support in Palliative Rehabilitation.
25:358-365.
2018
-
Moving research into practice: summary report of the Ex/Cancer meeting on physical activity, exercise, and rehabilitation in oncology.
25:E615-E621.
2018
-
Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.
25:384-392.
2018
-
Survival of Patients with Subglottic Squamous Cell Carcinoma.
25:e569-e575.
2018
-
Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.
25:e576-e584.
2018
-
Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.
25:e461-e474.
2018
-
Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
25:317-328.
2018
-
Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites.
25:300-306.
2018
-
Is there a role for adjuvant therapy after surgery in “high risk for recurrence” kidney cancer? An update on current concepts.
25:e444-e453.
2018
-
Neoadjuvant therapy for breast cancer: updates and proceedings from the Seventh Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer.
25:1-9.
2018
-
Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.
25:329-337.
2018
-
Engaging cancer patients in clinical practice guideline development: a pilot study.
25:250-256.
2018
-
Anastomosing hemangioma of the kidney: radiologic and pathologic distinctions of a kidney cancer mimic.
25:220-220.
2018
-
Antiangiogenic therapies in non-small-cell lung cancer.
25:45-45.
2018
-
Clinical practice guidelines in breast cancer.
25:151-151.
2018
-
Comprehensive metastatic lung cancer care must include palliative care.
25:192-192.
2018
-
Connecting people with cancer to physical activity and exercise programs: a pathway to create accessibility and engagement.
25:149-149.
2018
-
Standardizing biomarker testing for Canadian patients with advanced lung cancer.
25:73-73.
2018
-
Feasibility of assessing patient health benefits and incurred costs resulting from early dysphagia intervention during and immediately after chemoradiotherapy for head-and-neck cancer.
24:466-466.
2017
-
Identifying barriers to accrual in radiation oncology randomized trials.
24:524-524.
2017
-
Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.
24:540-540.
2017
-
Staging and surgical approaches in gastric cancer: a clinical practice guideline.
24:324-324.
2017
-
Systemic therapy in incurable gastroenteropancreatic neuroendocrine tumours: a clinical practice guideline.
24:249-249.
2017
-
Palliative care as a public health issue: understanding disparities in access to palliative care for the homeless population living in Toronto, based on a policy analysis.
24:187-187.
2017
-
Quality of life for patients surviving cancer: are we moving ahead?.
24:151-151.
2017
-
Challenges and insights in implementing coordinated care between oncology and primary care providers: a Canadian perspective.
24:120-120.
2017
-
Comparative survival in patients with brain metastases from non-small-cell lung cancer treated before and after implementation of radiosurgery.
24:146-146.
2017
-
Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario.
24:103-103.
2017
-
Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.
24:111-111.
2017
-
Multigene expression profile testing in breast cancer: is there a role for family physicians?.
24:95-95.
2017
-
Systemic therapy in the curative treatment of head-and-neck squamous cell cancer: Cancer Care Ontario clinical practice Guideline.
24:157-157.
2017
-
Uptake of a 21-gene expression assay in breast cancer practice: views of academic and community-based oncologists.
24:138-138.
2017
-
A Canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma.
24:33-33.
2017
-
Does adjuvant radiation therapy benefit women with small mammography-detected breast cancers?.
24:28-28.
2017
-
Examining the medical resource utilization and costs of relapsed and refractory chronic lymphocytic leukemia in Ontario.
24:50-50.
2017
-
Guideline for radiotherapy with curative intent in patients with early stage, medically inoperable, non-small cell lung cancer.
24:44-44.
2017
-
Introducing Dr. Matthew Seftel.
24:7-7.
2017
-
Moving guidelines into action: a report from Cancer Care Ontario’s event Let’s Get Moving: Exercise and Rehabilitation for Cancer Patients.
24:65-65.
2017
-
Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline.
23:418-418.
2016
-
Early palliative care: taking ownership and creating the conditions.
23:367-367.
2016
-
Clinical surveillance compared with clinical and magnetic resonance imaging surveillance for brain metastasis: a feasibility survey.
23:356-356.
2016
-
Follow-up care for survivors of lymphoma who have received curative-intent treatment.
23:499-499.
2016
-
Follow-up of patients who are clinically disease-free after primary treatment for fallopian tube, primary peritoneal, or epithelial ovarian cancer: a Program in Evidence-Based Care guideline adaptation.
23:343-343.
2016
-
Approach to fever assessment in ambulatory cancer patients receiving chemotherapy: a clinical practice guideline.
23:280-280.
2016
-
Fee-for-service cancer rehabilitation programs improve health-related quality of life.
23:233-233.
2016
-
Approach to biomarker testing: perspectives from various specialties.
23:178-178.
2016
-
Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE study.
23:276-276.
2016
-
Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.
23:196-196.
2016
-
Implementing low-dose computed tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency, and duration.
23:179-179.
2016
-
Management of small-cell lung cancer with radiotherapy—a pan-Canadian survey of radiation oncologists.
23:184-184.
2016
-
Accrual of adolescents and young adults with cancer to clinical trials.
23:81-81.
2016
-
Collaborative case conferences in rectal cancer: case series in a tertiary care centre.
23:138-138.
2016
-
Follow-up for cervical cancer: a Program in Evidence-Based Care systematic review and clinical practice guideline update.
23:109-109.
2016
-
Cost trajectories for cancer patients.
23:64-64.
2016
-
Eastern Canadian Colorectal Cancer Consensus Conference 2013: emerging therapies in the treatment of pancreatic, rectal, and colorectal cancers.
23:52-52.
2016
-
Temporal association between home nursing and hospital costs at end of life in three provinces.
23:42-42.
2016
-
Worth his weight in….
22:372-372.
2015
-
Are patients receiving the right care in the right place at the right time?.
22:315-315.
2015
-
Quality of end-of-life cancer care in Canada: a retrospective four-province study using administrative health care data.
22:341-341.
2015
-
Diagnosing lung cancer in the 21st century: are we ready to meet the challenge of individualized care?.
22:272-272.
2015
-
The optimal organization of gynecologic oncology services: a systematic review.
22:282-282.
2015
-
The organization of colposcopy services in Ontario: recommended framework.
22:287-287.
2015
-
Views of family physicians about survivorship care plans to provide breast cancer follow-up care: exploration of results from a randomized controlled trial.
22:252-252.
2015
-
Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline.
22:211-211.
2015
-
Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic review.
22:183-183.
2015
-
Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5–6, 2014.
22:113-113.
2015
-
Erratum: Tumour inflammatory response: adding fuel to the fire?.
22:133-133.
2015
-
Guidelines on the use of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal surface malignancy arising from colorectal or appendiceal neoplasms.
22:100-100.
2015
-
Secular trends in the survival of patients with laryngeal carcinoma, 1995–2007.
22:85-85.
2015
-
A Canadian national expert consensus on neoadjuvant therapy for breast cancer: linking practice to evidence and beyond.
22:43-43.
2015
-
Locoregional therapy of locally advanced breast cancer: a clinical practice guideline.
22:54-54.
2015
-
Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations.
22:49-49.
2015
-
Safe handling of cytotoxics: guideline recommendations..
22:e27-e37.
2015
-
Tumour inflammatory response: adding fuel to the fire?.
22:7-7.
2015
-
A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults.
21:234-234.
2014
-
A systematic review of active treatment options in patients with desmoid tumours.
21:613-613.
2014
-
Bortezomib in multiple myeloma: systematic review and clinical considerations.
21:573-573.
2014
-
Factors associated with publication of randomized phase iii cancer trials in journals with a high impact factor.
21:564-564.
2014
-
Treatment and follow-up strategies in desmoid tumours: a practice guideline.
21:642-642.
2014
-
Access to personalized medicine: factors influencing the use and value of gene expression profiling in breast cancer treatment.
21:426-426.
2014
-
Metastatic renal cell carcinoma without evidence of a primary renal tumour.
21:521-521.
2014
-
Utilization of stereotactic ablative radiotherapy in the management of oligometastatic disease.
21:115-115.
2014
-
Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome–positive or BCR-ABL–positive acute lymphoblastic leukemia: a Canadian consensus.
21:265-265.
2014
-
Patients’ perceptions of gene expression profiling in breast cancer treatment decisions.
21:203-203.
2014
-
Practice and documentation of palliative sedation: a quality improvement initiative.
21:100-100.
2014
-
Rasch analysis of the Edmonton Symptom Assessment System and research implications.
21:186-186.
2014
-
A Canadian perspective on the safe administration of bendamustine and the prevention and management of adverse events.
21:35-35.
2014
-
Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis.
21:96-96.
2014
-
Oncology education in Canadian undergraduate and postgraduate medical programs: a survey of educators and learners.
21:75-75.
2014
-
Optimizing outcomes with azacitidine: recommendations from Canadian centres of excellence.
21:44-44.
2014
-
A prospective evaluation of an interdisciplinary nutrition–rehabilitation program for patients with advanced cancer.
20:310-310.
2013
-
An interprofessional palliative care oncology rehabilitation program: effects on function and predictors of program completion.
20:301-301.
2013
-
Outcomes of her2-positive early-stage breast cancer in the trastuzumab era: a population-based study of Canadian patients.
20:539-539.
2013
-
The association between malnutrition and psychological distress in patients with advanced head-and-neck cancer.
20:554-554.
2013
-
Canadian integrative oncology research priorities: results of a consensus-building process.
20:289-289.
2013
-
Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases.
20:300-300.
2013
-
Surgical margins and handling of soft-tissue sarcoma in extremities: a clinical practice guideline.
20:247-247.
2013
-
A comparison of patient knowledge of clinical trials and trialist priorities.
20:193-193.
2013
-
Liver resection for colorectal cancer metastases.
20:255-255.
2013
-
Management of renal collecting duct carcinoma: a systematic review and the McMaster experience.
20:223-223.
2013
-
The growing pains of cancer survivors: a call for a paradigm of interdisciplinary care..
20:e57-e58.
2013
-
Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario.
20:e21-e33.
2013
-
Consensus recommendations for cancer rehabilitation: research and education priorities.
20:64-69.
2013
-
Endocrine therapy for postmenopausal women with hormone receptor–positive her2–negative advanced breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy: a Canadian consensus statement.
20:48-61.
2013
-
Response to: What is the optimal management of dysphagia in metastatic esophageal cancer?.
19.
2012
-
Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer.
19:e422-e427.
2012
-
Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.
19:259-268.
2012
-
Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma.
19:e270-e279.
2012
-
Management of a suspicious adnexal mass: a clinical practice guideline.
19:e244-e257.
2012
-
Casting stones and casting aspersions: let’s not lose sight of the main issues in the euthanasia debate.
19:139-142.
2012
-
Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study.
19:e129-e135.
2012
-
Fertility risk discussions in young patients diagnosed with colorectal cancer.
19:155-159.
2012
-
The importance of multidisciplinary team management of patients with non-small-cell lung cancer.
19:S7-S15.
2012
-
Extending neoadjuvant care through multi-disciplinary collaboration: proceedings from the fourth annual meeting of the Canadian Consortium for Locally Advanced Breast Cancer.
19:106-114.
2012
-
What is the optimal management of dysphagia in metastatic esophageal cancer?.
19.
2012
-
A call for action in survivorship research and care.
19:16-20.
2012
-
Challenges in knowledge translation: the early years of Cancer Care Ontario’s Program in Evidence-Based Care.
19:27-35.
2012
-
Fine-needle aspiration biopsy versus core-needle biopsy in diagnosing lung cancer: a systematic review.
19:e16-e27.
2012
-
Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis.
19:e9-e15.
2012
-
Phenytoin toxicity in a patient receiving 5-fluorouracil–based chemotherapy for metastatic colorectal cancer.
18:264-265.
2011
-
Survivorship services for adult cancer populations: a pan-Canadian guideline.
18:e265-e281.
2011
-
Establishing a multicentre clinical research network: lessons learned.
18:e243-e249.
2011
-
Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma..
18 Suppl 2:S11-S19.
2011
-
Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer..
18 Suppl 2:S5-S10.
2011
-
CML biology for the clinician in 2011: six impossible things to believe before breakfast on the way to cure.
18:e185-e190.
2011
-
Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer.
18:e180-e184.
2011
-
Prophylactic feeding tubes for patients with locally advanced head-and-neck cancer undergoing combined chemotherapy and radiotherapy—systematic review and recommendations for clinical practice.
18:e191-e201.
2011
-
Improving cancer control in Canada one case at a time: the “Knowledge Translation in Cancer” casebook.
18:76-83.
2011
-
Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls.
18:e38-e45.
2011
-
Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: NCIC CTG OV.21.
18:84-90.
2011
-
A comparative analysis of monthly out-of-pocket costs for patients with breast cancer as compared with other common cancers in Ontario, Canada.
18:e1-e8.
2011
-
Terry Fox's legacy: a case for translational research.
17:262-263.
2010
-
Cancer nutrition rehabilitation program: the role of social work.
17:12-17.
2010
-
Terry Fox’s legacy: a case for translational research.
17:2-3.
2010
-
Current management of castrate-resistant prostate cancer.
17:S72-S79.
2010
-
Optimizing the management of HER2-positive early breast cancer: the clinical reality.
17:154-167.
2010
-
Optimizing the management of HER2-positive early breast cancer: the clinical reality.
17:20-33.
2010
-
Follow-up for women after treatment for cervical cancer.
17:65-69.
2010
-
Estimating the national wage loss from cancer in Canada.
17:40-49.
2010
-
Feasibility of administering zoledronic acid in palliative patients being cared for in the community: results of a pilot study.
17:69-74.
2010
-
Current management of castrate-resistant prostate cancer.
17.
2010
-
Cancer diagnostic assessment programs: standards for the organization of care in Ontario.
16:29-41.
2009
-
Clinician-patient communication: evidence-based recommendations to guide practice in cancer.
16:398-405.
2009
-
Clinician-patient communication: evidence-based recommendations to guide practice in cancer.
16:42-49.
2009
-
Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer.
16:13-20.
2009
-
131I-tositumomab in lymphoma.
16:32-47.
2009
-
I-Tositumomab in lymphoma..
16:32-47.
2009
-
The Role of Neoadjuvant HER2-Targeted Therapies in HER2 Overexpressing Breast Cancers.
16:48-57.
2009
-
The Role of HER2-targeted Therapies in Women with HER2-Overexpressing Metastatic Breast Cancer.
16:25-35.
2009
-
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.
16:235-245.
2009
-
Novel developments in angiogenesis cancer therapy.
16:191-195.
2009
-
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma..
16 Suppl 1:S60-S66.
2009
-
Hormone replacement therapy and outcome for women with non-small cell lung cancer: can an association be confirmed?.
16:21-25.
2009
-
Novel developments in angiogenesis cancer therapy.
16:50-54.
2009
-
Role of cytokine therapy for Renal Cell Carcinoma in the era of targeted agents.
16:S40-S44.
2009
-
A Framework for the Organization and Delivery of Systemic Treatment.
16:4-15.
2009
-
Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.
16:S62-S68.
2009
-
I-131-Tositumomab in lymphoma.
16:32-47.
2009
-
Inhibition of mTOR in kidney cancer.
16:S35-S41.
2009
-
The role of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Therapy for Advanced, Metastatic and Recurrent Non-Small Cell Lung Cancer: A Canadian National Consensus Statement.
16:27-48.
2009
-
Chemotherapy-induced small bowel perforation in a patient with extrapulmonary small-cell carcinoma of the small bowel.
15:44-47.
2008
-
Chemotherapy-induced small bowel perforation in a patient with extrapulmonary small-cell carcinoma of the small bowel..
15:298-301.
2008
-
The Colon Health and Life-Long Exercise Change (CHALLENGE) trial (CO.21).
15:279-285.
2008
-
The Colon Health and Life-Long Exercise Change trial: A randomized trial of the National Cancer Institute of Canada Clinical Trials Group.
15:8-16.
2008
-
The Colon Health and Life-Long Exercise Change trial: a randomized trial of the National Cancer Institute of Canada Clinical Trials Group.
15:262-270.
2008
-
Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group.
15:179-184.
2008
-
Defining the optimal treatment strategy for localized prostate cancer patients: A survey of ongoing studies at the National Cancer Institute of Canadia Clinical Trials Group.
15:14-19.
2008
-
Editorial: Integrative Oncology and an Integrative Cancer Journal.
15:166-167.
2008
-
Healing and Survivorship: What Makes a Difference?.
15:185-187.
2008
-
Healing and survivorship: What makes a difference?.
15:20-22.
2008
-
How do we evaluate outcome in an integrative oncology program?.
15:s78-s82.
2008
-
Integrative Oncology: A Canadian and International Perspective.
15:s71-s73.
2008
-
RESEARCH AND REGULATORY ISSUES FOR INTEGRATIVE ONCOLOGY.
15:s107.es53-s108.es63..
2008
-
Cancer Nutrition and Rehabilitation – Its Time has Come!.
15:117-122.
2008
-
Chinese Medicine and Biomodulation in Cancer Patients (Part One).
15:42-48.
2008
-
Chinese Medicine and Biomodulation in Cancer Patients (Part Two).
15:8-30.
2008
-
Research and regulatory issues for integrative oncology.
15:S53-S63.
2008
-
Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer.
14:195-208.
2007
-
Treatment of Depression in Cancer Patients.
14:180-188.
2007
-
Phase II Testing of Sunitinib: The NCIC CTG IND Program Trials IND.182 - 185.
14:154-161.
2007
-
Alemtuzumab in Chronic Lymphocytic Leukemia: A Systematic Review and Clinical Practice Guideline.
14:96-109.
2007
-
A Tale of Two Time Periods: Ovarian Cancer Trends in Ontario.
14:57-60.
2007
-
Addition of Lenalidomide to Melphalan in the Treatment of Newly Diagnosed Multiple Myeloma: The NCIC CTG MY.11 Trial.
14:61-65.
2007
-
Massage Therapy for Cancer Patients: A Reciprocal Relationship Between Body and Mind.
14:45-56.
2007
-
Radiofrequency Ablation and Cryoablation of Renal Tumours.
14:34-38.
2007
-
Cross-border referral for early breast cancer: an analysis of radiation fractionation patterns..
13:124-129.
2006
-
Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review..
13:81-93.
2006
-
Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2..
13:99-107.
2006
-
Promoting best gynecologic oncology practice: a role for the Society of Gynecologic Oncologists of Canada..
13:94-98.
2006
-
Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1..
13:14-26.
2006
-
Role of bisphosphonates in the management of skeletal complications in patients with multiple myeloma.
12:3-17.
2005
-
Psychological, physical, social and economic impact of traveling great distances for cancer treatment.
12:1-7.
2005
-
Role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer.
11:41-52.
2004
-
Thyroid function screening following radiation therapy for cancers of the head and neck: A survey of Canadian practice patterns.
11:68-71.
2004
-
Role of amifostine as a radioprotectant in the management of patients with squamous cell head and neck cancer.
10:146-160.
2003
-
Role of octreodite in the management of patients with cancer.
10:161-179.
2003
-
Role of taxanes in the management of metastatic breast cancer.
10:68-83.
2003
-
Use of gemcitabine in non-small-cell lung cancer.
10:3-26.
2003
-
Use of bisphosphonates in breast cancer metastatic to bone: Compliance with practice guidelines.
9:7-12.
2002
-
The role of single-agent docetaxel as second-line treatment for advanced non-small-cell lung cancer.
8:50-59.
2001
-
Use of irinotecan combined with 5-fluorouracil and leucovorin as first-line therapy for metastatic colorectal cancer.
8:60-68.
2001
-
Accelerated radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
8:16-27.
2001
-
Hyperfractionated radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
8:6-15.
2001
-
Treatment of locally advanced squamous cell carcinoma of the head and neck: A summary and overview.
8:3-5.
2001
-
Drug therapy for chronic myeloid leukaemia.
7:229-241.
2000
-
Participation patterns of oncologists in the development of clinical practice guidelines.
7:252-257.
2000
-
The use of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer and methods of assessing HER2/neu status - An evidence summary.
7:242-251.
2000
-
Use of amifostine to ameliorate the toxic effects of chemotherapy in the treatment of cancer.
7:149-161.
2000
-
Use of topotecan in pre-treated recurrent or relapsed ovarian cancer patients.
7:136-148.
2000
-
Use of capecitabine in stage IV breast cancer: An evidence summary.
7:84-90.
2000
-
Use of irinotecan in secondline treatment of metastatic colorectal carcinoma.
7:29-36.
2000
-
'Two solitudes' or 'A mouse in bed with two elephants'.
7:3-4.
2000
-
Use of vinorelbine in stage IV breast cancer: An evidence summary.
7:24-28.
2000
-
Altered fractionation of radical radiaton therapy in the management of unresectable non-small-cell lung cancer.
7:98-109.
2000
-
Optimum radiation fractionation for T1 N0 glottic carcinoma.
7:91-97.
2000
-
The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer.
7:162-172.
2000
-
Humanised antibodies for cancer therapy. Part 2: Review of clinical trials with rituximab and trastuzumab.
6:131-137.
1999
-
Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients.
6:155-160.
1999
-
Use of biphosphonates in patients with bone metastases from breast cancer.
6:144-154.
1999
-
Use of rituximab in the treatment of lymphoma: An evidence summary.
6:228-235.
1999
-
The role of fludarabine in intermediate- and high-risk chronic lymphocytic leukaemia.
6:90-102.
1999
-
Humanized antibodies for cancer therapy. Part 1: Humanizing mouse antibodies.
6:74-77.
1999
-
The role of adjuvant systemic therapy in node-negative breast cancer.
6:78-89.
1999
-
Predictors of intention to act: High-school students and cervical screening.
6:36-42.
1999
-
New initiatives in the management of recurrent breast cancer.
5:188-194.
1998
-
Bisphosphonates for bone metastases in breast cancer patients: Trial design issues and evaluation of published studies.
5:181-187.
1998
-
Bone metastases: A review of their pathogenesis.
5:114-118.
1998
-
Recent reports in breast cancer.
5:143-147.
1998
-
High-grade glioma management and response assessment—recent advances and current challenges.
23:383-383.
-
Hormone replacement therapy and outcomes for women with non-small-cell lung cancer: can an association be confirmed?
2009
-
The 4th Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake
2009
-
The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake
2008
-
22nd Annual San Antonio Breast Cancer Symposium, December 8-11, 1999
1999
-
35th Annual Meeting of the American Society of Clinical Oncology: What's new in breast cancer
1999
-
21st Annual San Antonio Breast Cancer Symposium, December 12-15, 1998
1999
-
20th annual San Antonio Breast Cancer Symposium, December 3-6, 1997
1998
-
International St. Gallen conference: Adjuvant therapy of primary breast cancer, February 25-28, 1998
1998
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)